HC Wainwright Analysts Increase Earnings Estimates for RAPP

Rapport Therapeutics, Inc. (NASDAQ:RAPP – Free Report) – Research analysts at HC Wainwright boosted their FY2026 EPS estimates for Rapport Therapeutics in a report released on Thursday, November 5th. HC Wainwright analyst D. Tsao now expects that the company will earn ($3.18) per share for the year, up from their prior forecast of ($4.51). HC Wainwright has a “Buy” rating and a $66.00 price target on the stock. The consensus estimate for Rapport Therapeutics’ current full-year earnings is ($3.34) per share. HC Wainwright also issued estimates for Rapport Therapeutics’ Q4 2026 earnings at ($0.72) EPS, Q1 2027 earnings at ($0.91) EPS, Q2 2027 earnings at ($1.06) EPS, Q3 2027 earnings at ($1.12) EPS, Q4 2027 earnings at ($1.19) EPS, FY2027 earnings at ($4.29) EPS, FY2028 earnings at ($5.37) EPS, FY2029 earnings at ($5.56) EPS and FY2030 earnings at ($4.58) EPS.

RAPP has been the topic of a number of other reports. JonesTrading upped their price objective on Rapport Therapeutics from $50.00 to $82.00 and gave the company a “buy” rating in a research report on Wednesday, October 21st. William Blair began coverage on Rapport Therapeutics in a research report on Tuesday, July 28th. They set an “outperform” rating on the stock. TD Cowen reissued a “buy” rating on shares of Rapport Therapeutics in a research report on Tuesday, October 20th. Guggenheim decreased their price target on Rapport Therapeutics from $70.00 to $66.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Wall Street Zen raised shares of Rapport Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Rapport Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $64.50.

Read Our Latest Report on RAPP

Rapport Therapeutics Stock Performance

Shares of NASDAQ RAPP opened at $24.44 on Monday. Rapport Therapeutics has a 12-month low of $22.06 and a 12-month high of $52.93. The firm’s 50-day moving average price is $34.16 and its 200-day moving average price is $35.53. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of -7.71 and a beta of 1.40.

Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.84) EPS for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.36.

Institutional Trading of Rapport Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of RAPP. AlphaCentric Advisors LLC lifted its holdings in shares of Rapport Therapeutics by 6.8% in the 1st quarter. AlphaCentric Advisors LLC now owns 6,438 shares of the company’s stock worth $201,000 after buying an additional 408 shares during the period. Sterling Capital Management LLC lifted its position in shares of Rapport Therapeutics by 597.9% during the third quarter. Sterling Capital Management LLC now owns 984 shares of the company’s stock valued at $33,000 after buying an additional 843 shares during the last quarter. KBC Group NV purchased a new stake in Rapport Therapeutics during the first quarter valued at approximately $30,000. State of Wyoming acquired a new stake in Rapport Therapeutics in the second quarter valued at approximately $65,000. Finally, Swiss National Bank boosted its stake in Rapport Therapeutics by 3.5% in the first quarter. Swiss National Bank now owns 56,500 shares of the company’s stock valued at $1,768,000 after acquiring an additional 1,900 shares in the last quarter.

Insider Activity

In related news, Director Wendy Young purchased 3,789 shares of the business’s stock in a transaction dated Thursday, October 22nd. The shares were purchased at an average cost of $26.39 per share, for a total transaction of $99,991.71. Following the completion of the acquisition, the director owned 13,289 shares in the company, valued at approximately $350,696.71. This trade represents a 39.88% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director James Healy purchased 969,480 shares of Rapport Therapeutics stock in a transaction that occurred on Wednesday, October 28th. The stock was bought at an average cost of $21.00 per share, for a total transaction of $20,359,080.00. Following the purchase, the director directly owned 2,815,707 shares in the company, valued at $59,129,847. This trade represents a 52.51% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders bought 1,031,174 shares of company stock valued at $22,023,898 and sold 75,435 shares valued at $3,348,983. Company insiders own 12.48% of the company’s stock.

Key Stories Impacting Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

  • Positive Sentiment: HC Wainwright now forecasts FY2026 EPS of -$3.18, compared with its prior estimate of -$4.51, and FY2027 EPS of -$4.29, versus -$6.80 previously. Its estimates for FY2028, FY2029, and FY2030 were also revised to narrower losses. MarketBeat report
  • Positive Sentiment: The analyst also lowered projected losses for each quarter from Q4 2026 through Q4 2027, while maintaining its $66 price target and Buy rating. MarketBeat report
  • Neutral Sentiment: Despite the upgrades, HC Wainwright still expects Rapport to report losses in the periods cited; its revisions are improved forecasts, not a return to profitability.

About Rapport Therapeutics

(Get Free Report)

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.

See Also

Earnings History and Estimates for Rapport Therapeutics (NASDAQ:RAPP)

Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.